An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year. The three-year phase ...
Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback